XTL Bio

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) focuses on the acquisition and development of proprietary products and late-stage pharmaceutical product candidates for the treatment of unmet clinical needs. The company has two product candidates in clinical development: the hCDR1 peptide for Systemic Lupus Erythematosus (SLE), which has completed three clinical trials involving more than 400 patients, and Recombinant Erythropoietin (rHuEPO) for prolongation of multiple myeloma advanced-stage patients' survival and improvement of their quality of life. Its pipeline is generated by systematically identifying, validating and in-licensing therapeutic candidates with advantages over current therapies and which address unmet medical needs; three compounds are actively being developed, all in clinical stages.

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on the acquisition and development of proprietary products and late-stage pharmaceutical product candidates for the treatment of unmet clinical needs. The company has two product candidates in clinical development: the hCDR1 peptide for Systemic Lupus Erythematosus (SLE), which has completed three clinical trials involving more than 400 patients, and Recombinant Erythropoietin (rHuEPO) for prolongation of multiple myeloma advanced-stage patients' survival and improvement of their quality of life. Its pipeline is generated by systematically identifying, validating and in-licensing therapeutic candidates with advantages over current therapies and which address unmet medical needs; three compounds are actively being developed, all in clinical stages.

Clinical-stage biopharmaceutical company focused on acquisition and development of proprietary products and late-stage pharmaceutical product candidates for unmet clinical needs.

• hCDR1

  A novel compound, working via a novel mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE). It has completed three clinical trials involving more than 400 patients.

• Recombinant Erythropoietin (rHuEPO)

  A known compound being developed for the prolongation of multiple myeloma (MM) advanced-stage patients' survival and improvement of their quality of life.

1. 1XTLbioxtlbio.com
2. 2About Us | XTLbioxtlbio.com
3. 3Products Pipeline | XTLbioxtlbio.com
4. 4XTL Biowikidata.org